Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | DRD4 | P21917 | 7/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751430 | 0.91 | DRD4 (0.52) | DRD2DRD4DRD3ALDH1A1FAAH | |
| SCHEMBL5755013 | 0.88 | MCHR1 (0.50) | DRD2DRD4FAAHMCHR1MEN1 | |
| SCHEMBL14375335 | 0.81 | ACHE (0.62) | DRD2DRD4DRD3FAAHMCHR1 | |
| SCHEMBL17432875 | 0.81 | MEN1 (0.61) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| SCHEMBL5750626 | 0.80 | DRD4 (0.58) | DRD2DRD4DRD3ALDH1A1FAAH | |
| SCHEMBL5753239 | 0.79 | SSTR5 (0.58) | DRD2DRD4FAAHMCHR1ACHE | |
| SCHEMBL5752080 | 0.79 | MEN1 (0.58) | DRD2DRD4DRD3ALDH1A1FAAH | |
| SCHEMBL18926970 | 0.75 | HRH3 (0.55) | ALDH1A1FAAHROCK2 | |
| SCHEMBL8432504 | 0.75 | DRD4 (0.79) | DRD2DRD4DRD3MCHR1KCNH2 | |
| SCHEMBL30678678 | 0.74 | FAAH (0.58) | FAAHMCHR1ACHEKCNH2MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105543-B2 | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-09-12 | — | — | US | claimed |
| EP-1309586-B1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2006-03-22 | — | — | EP | claimed |
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-01-05 | — | — | US | claimed |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| US-7105543-B2 | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-09-12 | — | — | US | disclosed |
| EP-1309586-B1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-01-05 | — | — | US | disclosed |
| US-6958338-B2 | 4-,5-,6-and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-10-25 | — | — | US | disclosed |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| EP-1309586-A1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016349-A1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | HTR3C, SLC6A3, HTR6 | DRD2 6/4885DRD4 4/4885DRD3 5/4885 |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | HTR3C, HTR6, SLC6A3 | DRD2 12/4885DRD4 10/4885DRD3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.